1. Peters CJ, Zaki SR. Overview of viral hemorrhagic fevers. In: Guerrant RL, Walker DH, Weller PF, eds. Tropical Infectious Diseases: Principles, Pathogens, and Practice. Philadelphia, PA:
Churchill Livingstone; 2006:726–33.
2. Ebola virus disease in West Africa–the first 9 months of the epidemic and forward projections. N Engl J Med 2014;371(16):1481–95. (In eng). DOI: 10.1056/NEJMoa1411100.
3. Nsanzimana S, Remera E, Nkeshimana M, et al. Marburg Virus Disease in Rwanda, 2024 – Public Health and Clinical Responses. N Engl J Med 2025;393(10):983–993. DOI: 10.1056/NEJ-
Moa2415816.
4. Ergonul O. Crimean-Congo haemorrhagic fever. The Lancet infectious diseases 2006;6(4):203–14. (In eng)
5. Ergonul O, Whitehouse CA. Introduction. In: Ergonul O, Whitehouse CA, eds. Crimean Congo Hemorrhagic Fever: A Global Perspective. Dordrecht (NL): Springer; 2007:3–11.
6. Watts DM, Ksiasek TG, Linthicum KJ, Hoogstraal H. Crimean-Congo hemorrhagic fever. In Monath TP, editor. The arboviruses: epidemiology and ecology. Boca Raton, FL, USA: CRC, 1988.
7. Hoogstraal H. The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa. J Med Entomol 1979;15(4):307–417.
8. Simpson DIH, Knight EM, Courtois G, Williams MC, Weinbern MP, Kibukamusoke JW. Congo virus: a hitherto undescribed virus occuring in Africa, human isolations and clinical notes.
East Afr Med J 1967;44:87.
9. Casals J. Antigenic similarity between the virus causing Crimean hemorrhagic fever and Congo virus. Proc Soc Exp Biol Med 1969;131(1):233–6.
10. Woodall JP, Williams MC, Simpson DI. Congo virus: a hitherto undescribed virus occurring in Africa. II. Identification studies. East Afr Med J 1967;44:93–8.
11. Woodall JP. Personal Reflections. In: Ergonul O, Whitehouse CA, eds. Crimean Congo Hemorrhagic Fever: A Global Perspective. Dordrecht (NL): Springer; 2007:23–32.
12. Yen YC, Kong LX, Lee L, et al. Characteristics of Crimean-Congo hemorrhagic fever virus (Xinjiang strain) in China. Am J Trop Med Hyg 1985;34(6):1179–82.
13. Ergonul O. Crimean-Congo hemorrhagic fever virus: new outbreaks, new discoveries. Curr Opin Virol 2012;2(2):215–20. (In eng). DOI: S1879-6257(12)00044-2 [pii] 10.1016/j.covi-
ro.2012.03.001.
14. https://www.ecdc.europa.eu/sites/default/files/documents/crimean-congo-haemorrhagic%20fever-annual-epidemiological-report-2022.pdf (erişim tarihi 10 Eylül 2025)
15. Ergonul O, Celikbas A, Dokuzoguz B, Eren S, Baykam N, Esener H. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral
ribavirin therapy. Clin Infect Dis 2004;39(2):284–7.
16. Karti SS, Odabasi Z, Korten V, et al. Crimean-Congo hemorrhagic fever in Turkey. Emerg Infect Dis 2004;10(8):1379–84.
17. Bakir M, Ugurlu M, Dokuzoguz B, Bodur H, Tasyaran MA, Vahaboglu H. Crimean-Congo haemorrhagic fever outbreak in Middle Anatolia: a multicentre study of clinical features and out-
come measures. J Med Microbiol 2005;54(4):385–9.
18. Ozkurt Z, Kiki I, Erol S, et al. Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. The Journal of infection 2006;52(3):207–15.
(In eng)
19. Ergonul O, Battal I. Potential sexual transmission of Crimean-Congo hemorrhagic fever infection. Jpn J Infect Dis 2014;67(2):137–8. (In eng). DOI: DN/JST.JSTAGE/yoken/67.137 [pii].
20. CDC. Bioterrorism http://wwwbtcdcgov/Agent/Agentlistasp 2005(01 June 2005).
21. Flick R. Molecular Biology of the Crimean Congo Hemorrhagic Virus. In: Ergonul O, Whitehouse CA, eds. Crimean Congo Hemorrhagic Virus: A Global Perspective. Dordrecht (NL):
Springer; 2007:35–44.
22. Vatansever Z, Uzun R, Estrada-Pena A, Ergonul O. Crimean Congo Hemorrhagic Fever in Turkey. In: Ergonul O, Whitehouse CA, eds. Crimean Congo Hemorrhagic Fever: A Global Pers-
pective. Dordrecht (NL): Springer; 2007:59–74.
23. Midilli K, Gargili A, Ergonul O, et al. Crimean-Congo Haemorrhagic Fever in Istanbul. BMC Infect Dis 2007;7(54).
24. Midilli K, Gargili A, Ergonul O, et al. The first clinical case due to AP92 like strain of Crimean-Congo Hemorrhagic Fever virus and a field survey. BMC Infect Dis 2009;9:90. (In eng). DOI:
1471-2334-9-90 [pii] 10.1186/1471-2334-9-90.
25. Turell MJ. Role of Ticks in the Transmission of Crimean Congo Hemorrhagic Fever Virus. In: Ergonul O, Whitehouse CA, eds. Crimean Congo Hemorrhagic Fever: A Global Perspective.
Dordrecht (NL)2007:143–155.
26. van Eeden PJ, Joubert JR, van de Wal BW, King JB, de Kock A, Groenewald JH. A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part I. Clinical features.
S Afr Med J 1985;68(10):711–7.
27. Swanepoel R, Leman PA, Burt FJ, et al. Experimental infection of ostriches with Crimean-Congo haemorrhagic fever virus. Epidemiol Infect 1998;121(2):427–32.
28. Shepherd AJ, Swanepoel R, Leman PA, Shepherd SP. Field and laboratory investigation of Crimean-Congo haemorrhagic fever virus (Nairovirus, family Bunyaviridae) infection in birds. Trans
R Soc Trop Med Hyg 1987;81(6):1004–7.
29. Shepherd AJ, Swanepoel R, Shepherd SP, McGillivray GM, Searle LA. Antibody to Crimean-Congo hemorrhagic fever virus in wild mammals from southern Africa. Am J Trop Med Hyg
1987;36(1):133–42.
30. Estrada-Pena A. Forecasting habitat suitability for ticks and prevention of tick-borne diseases. Veterinary parasitology 2001;98(1-3):111–32. (In eng)
31. Randolph S, Rogers DF. Ecology of Tick-Borne Disease and the Role of Climate In: Ergonul O, Whitehouse CA, eds. Crimean Congo Hemorrhagic Fever: A Global Perspective. Dordrecht
(NL): Springer; 2007:167–186.
32. Randolph SE, Ergonul O. Crimean-Congo Hemorrhagic Fever: Exceptional Epidemic of Viral Hemorrhagic Fever in Turkey. Future Virol 2008;4(3):303–306.
33. Palomar AM, Portillo A, Santibanez P, et al. Crimean-Congo hemorrhagic fever virus in ticks from migratory birds, Morocco. Emerg Infect Dis 2013;19(2):260–3. (In eng). DOI: 10.3201/
eid1902.121193.
34. Estrada-Pena A, Palomar AM, Santibanez P, et al. Crimean-Congo hemorrhagic fever virus in ticks, Southwestern Europe, 2010. Emerg Infect Dis 2012;18(1):179–80. (In eng). DOI: 10.3201/
eid1801.111040.
35. Bausch DG KT. Viral hemorrhagic fevers including hantavirus pulmonary syndrome in the Americas Clinics in Laboratory Medicine 2002;22:981–1020.
36. Bray M. Comparative Pathogenesis of Crimean Congo Hemorrhagic Fever and Ebola Hemorrhagic Fever. In: Ergonul O, Whitehouse CA, eds. Crimean Congo Hemorrhagic Fever: A Global
Perspective. Dordrecht (NL): Springer; 2007:221–231.
37. Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. Nat Med 2004;10(12 Suppl):S110–21.
38. Peters CJ, Zaki SR. Role of the endothelium in viral hemorrhagic fevers. Critical care medicine 2002;30(5 Suppl):S268–73. (In eng)
39. Ergonul O, Tuncbilek S, Baykam N, Celikbas A, Dokuzoguz B. Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo he-
morrhagic fever. J Infect Dis 2006;193(7):941–4. (In eng)
40. Tasdelen Fisgin N, Fisgin T, Tanyel E, et al. Crimean-Congo hemorrhagic fever: Five patients with hemophagocytic syndrome. Am J Hematol 2007 (In Eng)
41. Cagatay A, Kapmaz M, Karadeniz A, et al. Haemophagocytosis in a patient with Crimean Congo haemorrhagic fever. J Med Microbiol 2007;56(Pt 8):1126–8. (In eng)
42. Celikbas A, Ergonul O, Dokuzoguz B, Eren S, Baykam N, Polat-Duzgun A. Crimean Congo hemorrhagic fever infection simulating acute appendicitis. The Journal of infection 2005;50(4):363–
5. (In eng)
43. Ergonul O. Clinical and Pathologic Features of Crimean Congo Hemorrhagic Fever. In: Ergonul O, Whitehouse CA, eds. Crimean Congo Hemorrhagic Fever: A Global Perspective. Dordrecht
(NL): Springer; 2007:207–220.
44. Goldfarb LG, Chumakov MP, Myskin AA, Kondratenko VF, Reznikova OY. An epidemiological model of Crimean hemorrhagic fever. Am J Trop Med Hyg 1980;29(2):260–4. (In eng)
45. Swanepoel R, Gill DE, Shepherd AJ, Leman PA, Mynhardt JH, Harvey S. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev Infect Dis 1989;11 Suppl 4:S794–800.
46. Ergonul O, Celikbas A, Baykam N, Eren S, Dokuzoguz B. Analysis of risk-factors among patients with Crimean-Congo haemorrhagic fever virus infection: severity criteria revisited. Clin
Microbiol Infect 2006;12(6):551–4. (In eng)
47. Dokuzoguz B, Celikbas AK, Gok SE, Baykam N, Eroglu MN, Ergonul O. Severity Scoring Index for Crimean-Congo Hemorrhagic Fever and the Impact of Ribavirin and Corticosteroids on
Fatality. Clin Infect Dis 2013;57(9):1270–1274. (In Eng). DOI: cit527 [pii]10.1093/cid/cit527.
48. Bausch DG. Marburg and Ebola viruses. PIER: The Physicians’ Information and Education Resource American College of Physicians, electronic publication: http://pieracponlineorg/physici-
ans/diseases/d891/d891html
49. Kayadibi H, Yapar D, Akdogan O, Ulusu NN, Baykam N. Hitit Index to distinguish patients with and without Crimean-Congo hemorrhagic fever. Ticks Tick Borne Dis 2019;10(5):1035–1040.
DOI: 10.1016/j.ttbdis.2019.05.010.
50. Shepherd AJ, Swanepoel R, Leman PA. Antibody response in Crimean-Congo hemorrhagic fever. Rev Infect Dis 1989;11 Suppl 4:S801–6.
51. Zeller H. Laboratory Diagnosis of Crimean Congo Hemorrhagic Fever. In: Ergonul O, Whitehouse CA, eds. Crimean Congo Hemorrhagic Fever: A Global Perspective. Dordrecht (NL):
Springer; 2007:233–243.
52. Burt FJ, Leman PA, Abbott JC, Swanepoel R. Serodiagnosis of Crimean-Congo haemorrhagic fever. Epidemiol Infect 1994;113(3):551–62.
53. Drosten C, Kummerer BM, Schmitz H, Gunther S. Molecular diagnostics of viral hemorrhagic fevers. Antiviral Res 2003;57(1-2):61–87.
54. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013;100(2):446–54.
55. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014;514(7520):47–53. (In eng).
56. Thi EP, Mire CE, Lee AC, et al. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature 2015;521(7552):362–5.
57. Warren TK, Shurtleff AC, Bavari S. Advanced morpholino oligomers: a novel approach to antiviral therapy. Antiviral Res 2012;94(1):80–8.
58. Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014;508(7496):402–5.
59. Group PIW, Multi-National PIIST, Davey RT, Jr., et al. A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. N Engl J Med 2016;375(15):1448–1456.
60. Mulangu S, Dodd LE, Davey RT, Jr., et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med 2019;381(24):2293–2303.
61. McCormick JB, King IJ, Webb PA, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986;314(1):20–6.
62. Watts DM, Ussery MA, Nash D, Peters CJ. Inhibition of Crimean-Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin. Am J Trop Med Hyg 1989;41(5):581–5.
63. Tignor GH, Hanham CA. Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection. Antiviral Res 1993;22(4):309–25.
64. Fisher-Hoch SP, Khan JA, Rehman S, Mirza S, Khurshid M, McCormick JB. Crimean Congo-haemorrhagic fever treated with oral ribavirin. Lancet 1995;346(8973):472–5.
65. Mardani M, Jahromi MK, Naieni KH, Zeinali M. The efficacy of oral ribavirin in the treatment of crimean-congo hemorrhagic fever in Iran. Clin Infect Dis 2003;36(12):1613–8.
66. Ergonul O. Treatment of Crimean Congo Hemorrhagic Fever. In: Ergonul O, Whitehouse CA, eds. Crimean Congo Hemorrhagic Fever: A Global Perspective. Dordrecht (NL): Springer;
2007:245–260.
67. Gullu D, Yigci D, Baykam N, et al. Key predictors of mortality in Crimean-Congo haemorrhagic fever: a retrospective multicentre cohort study. Clin Microbiol Infect 2025. DOI: 10.1016/j.
cmi.2025.08.009.
68. Ozbey SB, Kader C, Erbay A, Ergonul O. Early use of ribavirin is beneficial in Crimean-Congo hemorrhagic fever. Vector Borne Zoonotic Dis 2014;14(4):300–2.
69. Enria DA, Briggiler AM, Fernandez NJ, Levis SC, Maiztegui JI. Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet
1984;2(8397):255–6.
70. Enria DA, Mills JN, Flick R, et al. Arenavirus Infections. In: Guerrant RL, Walker DH, Weller PF, eds. Tropical Infectious Diseases. Principles, Pathogens and Practice, 2nd Ed. . Philadelphia
(PA): Elsevier Churchill Livingstone; 2006:734–755.
71. Vassilenko SM, Vassilev TL, Bozadjiev LG, Bineva IL, Kazarov GZ. Specific intravenous immunoglobulin for Crimean-Congo haemorrhagic fever. Lancet 1990;335(8692):791–2.
72. Russel JA. Management of sepsis. N Engl J Med 2006;355(16):1699–713.
73. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344(10):699–
709.
74. Panpanich R, Sornchai P, Kanjanaratanakorn K. Corticosteroids for treating dengue shock syndrome. Cochrane Database Syst Rev 2006(3):CD003488. DOI: 10.1002/14651858.CD003488.
pub2.
75. Rajapakse S. Corticosteroids in the treatment of dengue illness. Trans R Soc Trop Med Hyg 2009;103(2):122–6.
76. Hober D, Poli L, Roblin B, et al. Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) in dengue-infected patients. Am J Trop Med
Hyg 1993;48(3):324–31.
77. H. K. A Systematic Review of Treatment Strategies Including Future Novel Therapies in Crimean-Congo Hemorrhagic Fever. International Journal of Infection 2021;8(2).
78. Celikbas A, Ergonul O, Yildirim U, et al. Intrauterine infection of Crimean-Congo haemorrhagic fever: the courses of two episodes. 15th European Congress of Clinical Microbiology and
Infectious Diseases (ECCMID), Clin Microbiol Infect 12;4: p1665. Nice, France.2006.
79. Whitehouse CA. Risk Groups and Control Measures for Crimean Congo Hemorrhagic Fever. In: Ergonul O, Whitehouse CA, eds. Crimean-Congo Hemorrhagic Fever: A Global Perspe-
ctive. Dordrecht (NL): Springer; 2007:273–280.
80. Fisher-Hoch SP, McCormick JB, Swanepoel R, Van Middlekoop A, Harvey S, Kustner HG. Risk of human infections with Crimean-Congo hemorrhagic fever virus in a South African rural
community. Am J Trop Med Hyg 1992;47(3):337–45.
81. Tarantola A, Ergonul O, Tattevin P. Estimates and Prevention of Crimean Congo Hemorrhagic Fever Risks for Health care workers. In: Ergonul O, Whitehouse CA, eds. Crimean-Congo
Hemorrhagic Fever: A Global Perspective. Dordrecht (NL): Springer; 2007:281–294.
82. van de Wal BW, Joubert JR, van Eeden PJ, King JB. A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part IV. Preventive and prophylactic measures. S Afr
Med J 1985;68(10):729–32.
83. Ergonul O, Zeller HG, Celikbas A, Dokuzoguz B. The lack of Crimean-Congo hemorrhagic fever virus antibodies in healthcare workers in an endemic region. Int J Infect Dis 2007;11:48–51.
84. Celikbas AK, Dokuzoguz B, Baykam N, et al. Crimean-Congo Hemorrhagic Fever among Health Care Workers, Turkey. Emerg Infect Dis 2014;20(3):477–9.
85. Guner R, Hasanoglu I, Tasyaran MA, et al. Is ribavirin prophylaxis effective for nosocomial transmission of Crimean-Congo hemorrhagic fever? Vector Borne Zoonotic Dis 2014;14(8):601–5.
86. Bausch DG, Hadi CM, Khan SH, Lertora JJ. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis
2010;51(12):1435–41.
87. Angelin M, Sjolin J, Kahn F, et al. Qdenga(R) – A promising dengue fever vaccine; can it be recommended to non-immune travelers? Travel Med Infect Dis 2023;54:102598..
88. World Health Organization. Dengue and severe dengue. (https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue).
89. Patel SS, Winkle P, Faccin A, Nordio F, LeFevre I, Tsoukas CG. An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity
and safety when administered during the second half of a 24-month shelf-life. Hum Vaccin Immunother 2023;19(2):2254964.
90. Shaikh S, Chary PS, Mehra NK. Nano-interventions for dengue: a comprehensive review of control, detection and treatment strategies. Inflammopharmacology 2025;33(3):979–1011.
91. Team PS, Kieh M, Richert L, et al. Randomized Trial of Vaccines for Zaire Ebola Virus Disease. N Engl J Med 2022;387(26):2411–2424.
92. Papa A, Bozovi B, Pavlidou V, Papadimitriou E, Pelemis M, Antoniadis A. Genetic detection and isolation of crimean-congo hemorrhagic fever virus, Kosovo, Yugoslavia. Emerg Infect Dis
2002;8(8):852–4